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SCIENTIFIC OPINION 
Scientific opinion on applications EFSA-GMO-RX-T25 and EFSA-GMO-
NL-2007-46 for the renewal of authorisation of maize T25,
1
 and for the 
placing on the market of herbicide-tolerant genetically modified maize 
T25,
2
 both for food and feed uses, import and processing under Regulation 
(EC) No 1829/2003 from Bayer CropScience AG 
EFSA Panel on Genetically Modified Organisms (GMO)
3,4
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
This scientific opinion reports on a risk assessment for the authorisation for (continued) marketing of genetically 
modified maize T25 for food and feed uses, import and processing. Maize T25 contains a single insertion locus 
containing a pat cassette conferring tolerance to glufosinate-based herbicides. Bioinformatic analyses, protein 
expression data and genetic stability studies did not raise safety issues. The compositional, agronomic and 
phenotypic characteristics of maize T25 grain and its conventional counterpart showed no differences that are of 
relevance for food/feed safety. The safety assessment identified no concerns regarding the potential toxicity and 
allergenicity of the newly introduced PAT protein. The compositional data indicating the nutritional equivalence 
of maize T25 were supported by the results of the feeding studies. There was no evidence that the genetic 
modification might significantly change the overall allergenicity of maize T25. Considering all available 
information related to the agronomic and phenotypic characterisation of maize T25, the EFSA GMO Panel did 
not observe any enhanced fitness characteristics of maize T25 that will change its capacity to spread, establish or 
persist compared with non-genetically modified (GM) maize, except in the presence of glufosinate-based 
herbicides. Considering its intended uses as food and feed, interactions with the biotic and abiotic environment 
were not considered an issue. Risks associated with an unlikely but theoretically possible horizontal gene 
transfer from maize T25 to bacteria have not been identified. The monitoring plan and reporting intervals were in 
line with the intended uses. The Panel concluded that maize T25, as described in the applications, is as safe as its 
conventional counterpart with respect to potential effects on human and animal health or the environment in the 
context of its intended uses for food and feed, import and processing. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the Competent Authority of the Netherlands and from the European 
Commission (EC), the Panel on Genetically Modified Organisms of the European Food Safety 
Authority (EFSA GMO Panel) was asked to deliver a scientific opinion on applications EFSA-GMO-




Application EFSA-GMO-RX-T25 was initially for renewal of the authorisation for continued 
marketing of: 
 foods and food ingredients produced from maize T25 which have been placed on the market in 
accordance with Art. 5 of Regulation (EC) No 258/97;
6
 
 feed containing, consisting of or produced from maize T25 (feed materials and feed additives) 
which has been placed on the market in accordance with Part C of Directive 90/220/EEC;
7
 
 seeds for cultivation; Commission Decision of 22 April 1998 concerning the placing on the 
market of genetically modified maize (Zea mays L. T25), pursuant to Council Directive 
90/220/EEC. 
After the date of entry into force of Regulation (EC) 1829/2003, the products mentioned above were 
notified to the EC in accordance with Article 8(1)(b) or 20(1)(b) of this Regulation and subsequently 
included in the Community Register of genetically modified (GM) food and feed. 
Application EFSA-GMO-NL-2007-46 was initially for food and feed uses, import and processing of 
maize T25 and all derived products, and cultivation of maize T25 in the European Union (EU).  
Following the applicant‘s request to modify the scope of applications EFSA-GMO-RX-T25 and 
EFSA-GMO-NL-2007-46 to no longer include cultivation of maize T25 in the EU, the EFSA GMO 
Panel provides a single scientific opinion, valid for both applications. 
The EFSA GMO Panel assessed maize T25 with reference to the intended uses and appropriate 
principles described in its Guidance Documents for the risk assessment of GM plants and derived food 
and feed (EFSA, 2006a) and for renewal of authorisations of existing GMO products lawfully placed 
on the market (EFSA, 2006b). In delivering its scientific opinion, the EFSA GMO Panel considered 
applications EFSA-GMO-RX-T25 and EFSA-GMO-NL-2007-46, additional information submitted by 
the applicant at the request of the Panel, the scientific comments submitted by Member States and 
relevant scientific publications. In accordance with its guidance document for renewal of 
authorisations of existing GMO products (EFSA, 2006b), the EFSA GMO Panel took into account the 
new information, experience and data on maize T25 that became available during the authorisation 
period. The scientific evaluation of the risk assessment included molecular characterisation of the 
inserted DNA and expression of the target proteins. Evaluation of the comparative analysis of 
agronomic and phenotypic traits and composition was undertaken and the safety of the new proteins 
and the whole food/feed was evaluated with respect to potential toxicity, allergenicity and nutritional 
quality. An assessment was made of environmental impacts and the necessity for a post-market 
environmental monitoring plan. 
                                                     
5 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically 
modified food and feed. OJ L 268, 1–23. 
6 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and 
novel food ingredients. OJ L 43, 1–6. 
7 Council Directive 90/220/EEC of 23 April 1990 on the deliberate release into the environment of genetically modified 
organisms. OJ L 117, 15–27. 
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The molecular characterisation data established that the genetically modified maize T25 contains a 
single insertion locus containing a pat cassette. Bioinformatic analyses, protein expression data and 
genetic stability studies did not raise safety issues.  
The EFSA GMO Panel concluded that the compositional, agronomic and phenotypic characteristics of 
grain maize T25 and its conventional counterpart showed no differences of relevance for food/feed 
safety.  
The EFSA GMO Panel has evaluated the safety of the PAT protein in the context of the present 
application and several previous applications, and no safety concerns were identified. 
The EFSA GMO Panel considered that there are no indications of concern relevant for food and feed 
safety arising from the comparative compositional assessment of maize T25. The compositional data 
indicating the nutritional equivalence of maize T25 were supported by the results of feeding studies 
with dairy cows and chickens. In addition, there is no evidence that the genetic modification might 
significantly change the overall allergenicity of maize T25. The EFSA GMO Panel concluded that 
maize T25 is as safe and nutritious as its conventional counterpart in the context of its intended use. 
Applications EFSA-GMO-RX-T25 and EFSA-GMO-UK-2007-46 concern food and feed uses, import 
and processing. Therefore, there is no requirement for scientific information on possible 
environmental effects associated with the cultivation of maize T25. In accordance with its guidance 
document on the environmental risk assessment of GM plants (EFSA GMO Panel, 2010), the EFSA 
GMO Panel follows a weight of evidence approach in collating and assessing appropriate information 
from various data sources (e.g. molecular and compositional data, available agronomic and phenotypic 
data from field trials performed by the applicant, literature) in order to assess the likelihood of 
unintended effects on the environment. Considering all available information related to the agronomic 
and phenotypic characterisation of maize T25, the EFSA GMO Panel did not observe any enhanced 
fitness characteristics of maize T25 that will change its capacity to spread, establish or persist 
compared with non-GM maize, except in the presence of glufosinate-based herbicides. Considering its 
intended uses as food and feed, interactions with the biotic and abiotic environment were not 
considered to be an issue. Risks associated with an unlikely but theoretically possible horizontal gene 
transfer from maize T25 to bacteria have not been identified. The scope of the post-market 
environmental monitoring plan provided by the applicant was in line with the intended uses of maize 
T25. Furthermore, the EFSA GMO Panel agreed with the reporting intervals proposed by the applicant 
in the post-market environmental monitoring plan. 
In conclusion, the EFSA GMO Panel considered that maize T25, as described in applications EFSA-
GMO-RX-T25 and EFSA-GMO-NL-2007-46, is as safe as its conventional counterpart with respect to 
potential effects on human and animal health or the environment in the context of its intended uses for 
food and feed, import and processing. 
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BACKGROUND 
On 24 April 2007, the European Food Safety Authority (EFSA) received from the Netherlands 
Competent Authority an application (EFSA-GMO-NL-2007-46) for authorisation of genetically 
modified (GM) maize T25 (Unique Identifier ACS-ZMØØ3-2) submitted by Bayer CropScience AG 
within the framework of Regulation (EC) No 1829/2003 on GM food and feed. After receiving the 
application EFSA-GMO-NL-2007-46, and in accordance with Articles 5(2)(b) and 17(2)b of 
Regulation (EC) No 1829/2003, EFSA informed the Member States and the European Commission 
(EC) and made the summary of the application publicly available on the EFSA website.
8
 EFSA 
initiated a formal review of the application to check compliance with the requirements laid down in 
Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003. On 10 June 2008, EFSA declared the 
application as valid in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003. 
On 29 June 2007, EFSA received from the EC an application (EFSA-GMO-RX-T25) submitted under 
Regulation (EC) No 1829/2003 for renewal of the authorisation of maize T25 for all uses with the 
exception of food and food products derived from maize T25. 
The scope of the renewal application, as described in the Community Register,
9
 covers the continued 
marketing of: 
 Foods and food ingredients produced from maize T25 and all the varieties derived from starch and 
all its derivatives, crude, refined oil and all heat-processed or fermented products obtained from 
hominys, grits and flour (dry milled fragments) notified as existing foods falling within the scope 
of Article 8(1)(a) of Regulation (EC) No 1829/2003, which is produced from a genetically 
modified organism (GMO) and which have been placed on the market in accordance with Art. 5 of 
Regulation (EC) No 258/97; 
 Feed containing, consisting of, or produced from maize T25 (feed materials and feed additives) 
notified as existing feed falling within the scope of Article 20(1)(a) of Regulation (EC) No 
1829/2003, which consists of and/or contains a genetically modified organism (GMO) which has 
been placed on the market in accordance with Part C to the Directive 90/220/EEC; 
 Seeds for cultivation; Commission Decision of 22 April 1998 concerning the placing on the 
market of genetically modified maize (Zea mays L. T25), pursuant to Council Directive 
90/220/EEC. 
After receiving the renewal application EFSA-GMO-RX-T25 and in accordance with Articles 5(2)(b) 
and 17(2)b of Regulation (EC) No 1829/2003, EFSA informed Member States as well as the EC and 
made the summary of this application publicly available on the EFSA website.
10
 EFSA initiated a 
formal review of the renewal application to check compliance with the requirements laid down in 
Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003. On 9 October 2008, EFSA declared the 
application as valid in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003. 
On 26 February 2008, following a call for expression of interest among Competent Authorities under 
Directive 2001/18/EC and in accordance with Articles 6.3(c) and 18.3(c) of Regulation (EC) No 
1829/2003, EFSA requested the United Kingdom Competent Authority (UK CA) to evaluate the initial 
environmental risk assessment of application EFSA-GMO-NL-2007-46 for the placing on the market 
of maize T25 for cultivation. 
EFSA made the valid applications EFSA-GMO-NL-2007-46 and EFSA-GMO-RX-T25 available to 
Member States and the EC, and consulted nominated risk assessment bodies of Member States, 
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including national Competent Authorities within the meaning of Directive 2001/18/EC,
11
 to request 
their scientific opinion. The Member State bodies had 3 months after the date of receipt of the valid 
application (until 10 September 2008 and 9 January 2009, respectively) within which to make their 
opinion known. 
The UK CA asked the applicant for additional information on maize T25 on 1 October 2008. The 
applicant provided the requested information on 1 July 2009. 
The UK CA provided to EFSA its report on the environmental risk assessment of maize T25 on 17 
February 2012 in line with Articles 6.3(c) and 18.3(c) of Regulation (EC) No 1829/2003. 
On 14 January 2013, EFSA received from the applicant a request to modify the scope of applications 
EFSA-GMO-RX-T25 and EFSA-GMO-NL-2007-46 to no longer include cultivation of maize T25 in 
the EU. 
The Scientific Panel on Genetically Modified Organisms of EFSA (EFSA GMO Panel) carried out an 
evaluation of the risk assessment of the applications on maize T25 in accordance with the new scope 
and appropriate principles described in its guidance documents for the risk assessment of GM plants 
and derived food and feed (EFSA, 2006a) and for renewal of authorisations of existing GMO products 
lawfully placed on the market (EFSA, 2006b). In addition, the scientific comments of Member States, 
the additional information provided by the applicant and relevant scientific publications were taken 
into consideration.  
For both EFSA-GMO-RX-T25 and EFSA-GMO-NL-2007-46, the EFSA GMO Panel requested 
additional information from the applicant on 29 March 2012 and 24 May 2012. The applicant provided 
information related to both requests on 3 September 2012 and 18 December 2012. Following the 
change of scope in January 2013, the GMO Panel requested a PMEM plan according to the new scope 
on 4 February 2013. The applicant provided the requested information on 19 February 2013. 
On 11 July 2012, EFSA informed the applicant that, given that applications EFSA-GMO-RX-T25 and 
EFSA-GMO-NL-2007-46 had been processed for five years since their reception and the datasets 
received did not allow EFSA to conclude on the safety of maize T25, after 1 September 2012, which 
corresponded to the latest deadline to deliver additional information as specified by the applicant, 
EFSA would proceed with the finalisation of the assessment of EFSA-GMO-RX-T25 and EFSA-
GMO-NL-2007-46 and deliver its opinion based on the information available at that time. 
In giving its scientific opinion on maize T25 to the EC, the Member States and the applicant, and in 
accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has endeavoured to 
respect a time limit of 6 months from the acknowledgement of the valid application. As additional 
information was requested by the EFSA GMO Panel, the time limit of 6 months was extended 
accordingly, in line with Articles 6(1), 6(2), 18(1), and 18(2) of Regulation (EC) No 1829/2003. 
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report 
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the respective 
overall opinions in accordance with Articles 6(5) and 18(5). 
TERMS OF REFERENCE 
The EFSA GMO Panel was requested to carry out a scientific assessment of maize T25 (Unique 
Identifier: ACS-ZMØØ3-2) in the context of applications EFSA-GMO-RX-T25 and EFSA-GMO-NL-
2007-46. Considering the change of scope requested by the applicant, the scope of EFSA-GMO-RX-
T25 covers the renewal of authorisation of (1) foods and food ingredients produced from maize T25 
which have been placed on the market in accordance with Art. 5 of Regulation (EC) No 258/97 and 
(2) feed containing, consisting of, or produced from maize T25 (feed materials and feed additives) 
                                                     
11 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the 
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L106, 1–39. 
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which has been placed on the market in accordance with Part C to the Directive 90/220/EEC, and 
application EFSA-GMO-NL-2007-46 is for food and feed uses, import and processing of maize T25 
and all derived products. 
Where applicable, any conditions or restrictions which should be imposed on the placing on the 
market and/or specific conditions or restrictions for use and handling, including post-market 
monitoring requirements based on the outcome of the risk assessment and, in the case of GMOs or 
food/feed containing or consisting of GMOs, conditions for the protection of particular 
ecosystems/environments and/or geographical areas should be indicated in accordance with 
Articles 6(5)(e) and 18(5)e of Regulation (EC) No 1829/2003. 
The EFSA GMO Panel was not requested to give a scientific opinion on information required under 
Annex II of the Cartagena Protocol. Furthermore, the EFSA GMO Panel did not consider proposals 
for labelling and methods of detection (including sampling and the identification of the specific 
transformation event in the food/feed and/or food/feed produced from it), which are matters related to 
risk management. 
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ASSESSMENT 
1. Introduction 
Maize T25 was developed to express the enzyme phosphinothricin acetyl-transferase (PAT), encoded 
by the pat gene from Streptomyces viridochromogenes codon-optimised for expression in plants. 
Expression of PAT confers tolerance to glufosinate-based herbicides. 
The genetic modification in maize T25 is intended to improve agronomic performance only and is not 
intended to influence the nutritional properties, the processing characteristics and the overall use of 
maize as a crop. 
The GM maize T25 (Unique Identifier: ACS-ZMØØ3-2) was evaluated with reference to its intended 
uses, taking account of the appropriate principles described in the Guidance Documents of the EFSA 
GMO Panel for the risk assessment of GM plants and derived food and feed (EFSA, 2006a) and for 
the renewal of authorisations of existing GMO products lawfully placed on the market (EFSA, 2006b). 
The scope of application EFSA-GMO-RX-T25 covers the renewal of authorisation of (1) foods and 
food ingredients produced from maize T25 which have been placed on the market in accordance with 
Art. 5 of Regulation (EC) No 258/97 and (2) feed containing, consisting of or produced from maize 
T25 (feed materials and feed additives) which has been placed on the market in accordance with Part 
C of Directive 90/220/EEC, and the scope of EFSA-GMO-NL-2007-46 is for food and feed uses, 
import and processing of maize T25 and all derived products, as for any other commercial maize 
variety. 
The risk assessment presented here is based on the information provided in applications EFSA-GMO-
RX-T25 and EFSA-GMO-NL-2007-46 submitted in the EU including the additional information from 
the applicant and the scientific comments that were raised by Member States on these applications. 
A review of peer-reviewed scientific data on maize T25 and derived food and feed available since the 
original authorisation was provided by the applicant and did not raise issues impacting on the safety of 
maize T25 for humans and animals and for the environment. 
The applicant also provided a report on the areas and quantity of production, importation and 
utilisation of maize T25 in Europe and information on known and estimated human and animal 
exposure. 
A report on any unintended and/or unanticipated effects of maize T25 was not deemed applicable by 
the applicant as no general surveillance or case-specific monitoring was specified in the authorisation 
decision, and not provided. 
Sections 2 to 7 report on the risk assessment for application EFSA-GMO-RX-T25 and Section 8 
provides an assessment for the extended scope as indicated in EFSA-GMO-NL-2007-46. 
2. Issues raised by the Member States 
The scientific issues raised by the Member States are addressed in Annex G of the EFSA overall 
opinion and have been considered in this scientific opinion.
12,13
 
                                                     
12 http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2007-134 
13 http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2007-155 
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3. Molecular characterisation 
3.1. Evaluation of relevant scientific data 
3.1.1. Transformation process and vector constructs 
Maize T25 was developed by polyethylene glycol (PEG)-mediated transformation of protoplasts from 
the embryogenic cell suspension cultures of the maize genotype HE/89. The plasmid used for 
transformation contained a synthetic pat gene codon-optimised for expression in plants under the 
control of 35S promoter and terminator sequences derived from the Cauliflower mosaic virus (CaMV). 
The plasmid also included a β-lactamase (bla) gene and a bacterial origin of replication from pUC18.14 
3.1.2. Transgene constructs in the genetically modified plant15 
Data from Southern analysis (updated in 2012 with material produced in 2006 and 2012)
16
 
demonstrated that T25 maize contains a single insertion. The sequences actually inserted were 
determined by PCR amplification and sequence analysis. The insert contains a single copy of the 
P35S-pat-T35S expression cassette. The cassette is flanked at the 5  end by 604 bp of the pUC18 
plasmid including 5 bp of the bla gene and a fragment the lacZ gene. At the 3  end, the cassette is 
flanked by 1 840 bp of the pUC18 plasmid including the origin of replication and a 665-bp 3  fragment 
of the bla gene. The remainder of the bla gene (about 25 %) is not present in the insert.  
Analysis of the flanking sequences of the insert confirmed that these were maize sequences. 
Bioinformatic analyses (updated in 2012)
17
 showed that both the 3  and 5  flanking sequences have a 
high degree of similarity to the Huck-2 retrotransposon, present at high copy number in the maize 
genome. Considering that the majority of the maize genome is derived from transposable elements, 
insertion in a retrotransposable element is not unexpected and does not raise a safety concern. These 
analyses also showed that no known endogenous genes were disrupted by the insertion. 
An updated bioinformatic analysis (2012)
18
 was performed on all possible open reading frames 
(ORFs) within the insert and spanning the maize genomic DNA–T25 insert junctions. None of the 
theoretical peptides deduced from these new ORFs showed relevant similarity with known toxins or 
allergens.  
3.1.3. Information on the expression of the insert19 
Analysis of PAT protein expression was carried out by ELISA using plants grown in four different 
field locations in Canada in 1995, in the USA in 1995 and 2009 and in France in 2004.
20
 Considering 
the scope of the application, PAT protein levels in grain are considered the most relevant. Expression 
in grain ranged from below the limit of quantification to 0.43 g/g dry weight.
21
 Variations in protein 
expression values are not unexpected and can be due, for example, to differences in genetic 
background of the plants and/or environmental variables. Considering the nature of the PAT protein 
and the scope of the application, these variations in protein expression do not raise safety issues. 
Although a complete bla gene is not present in transformation event T25, β-lactamase assays and 
Northern blot analysis were performed and no partial bla transcripts or β-lactamase activity were 
detected. 
                                                     
14 Technical dossier/Section C. 
15 Technical dossier/Section D2. 
16 Additional information August 2012/Verhaeghe (2012b). 
17 Additional information August 2012/Verhaeghe (2012a). 
18 Additional information August 2012/Rascle (2012). 
19 Technical dossier/Section D3. 
20 Additional information August 2012. 
21 Additional information December 2012. 
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3.1.4. Inheritance and stability of inserted DNA 
The inheritance pattern of the T25 event was investigated by Southern analysis of plant material 
obtained from the original transformant and from individuals of the third back-crossing generation. 
The probe corresponding to the pat gene produced the expected band in all cases, indicating stability 
of the integrated DNA. Updated Southern analyses of a later T25 generation grown in 2012
16
 
confirmed the stability of the integrated DNA. The phenotypic stability was determined following the 
segregation of the trait over two generations after being introgressed into different inbred lines. 
Stability was also confirmed by evaluating the segregation of the tolerance to glufosinate-ammonium 
in crosses between hemizygous T25 and non-GM inbreds. The inheritance pattern of the glufosinate 
tolerance trait was consistent with a single genetic locus segregating in a Mendelian fashion. 
In conclusion, the stability of the inserted DNA and associated trait was confirmed over several 
generations. 
3.2. Conclusion 
The molecular characterisation data provided by the applicant established that the genetically modified 
maize T25 contains a single insertion locus containing a pat cassette. Updated bioinformatic analyses 
of the insert and flanking regions and protein expression data did not raise safety issues. The stability 
of the inserted DNA and the herbicide tolerance trait were confirmed over several generations and a 
Mendelian inheritance pattern was demonstrated. The EFSA GMO Panel concluded that the molecular 
characterisation does not raise safety issues. 
4. Comparative analysis 
4.1. Evaluation of relevant scientific data 
Compositional data were previously provided and assessed by the European Commission‘s Scientific 
Committee on Plants in its opinion published in 1998, in the frame for the approval of the 
environmental release including animal feed use of T25 maize under Directive 90/220/EEC (SCP, 
1998), and by the UK Advisory Committee on Novel Foods and Processes (ACNFP) in the frame of a 
notification for human food use of processed products derived from T25 maize as novel food under 
Regulation (EC) No 258/97 (ACNFP, 1997). The data provided with the dossier for the current 
application were obtained after the publication of these opinions. As the ACNFP had requested 
monitoring of compositional data over time, the applicant provided new compositional data in 2002 
(from 15 locations in the seasons 1999 and 2000, concurring with some of the data provided to EFSA; 
see Section 4.1.1). The ACNFP thus concluded that it was satisfied that the majority of components 
measured in T25 maize kernels fell within standard reference ranges for maize and that any of the 
statistically significant differences found between the three different test groups (GM maize treated or 
non-treated with target herbicide, conventional counterpart) were not of biological significance when 
viewed in the context of normal ranges (ACNFP, 2003). 
In the present application, the applicant provided data on sweet maize grown in the USA during two 
seasons, as well as compositional data on field maize. The sugar profiles of the sweet maize kernels 
indicated that compositional changes during post-harvest storage could not be excluded. The EFSA 
GMO Panel therefore decided not to consider these data. Thus, the compositional characteristics of 
maize T25 were based on data from field maize only. 
No data on forage composition were provided. 
4.1.1. Choice of comparator and production of material for the comparative analysis 
The field trials for the comparative compositional analysis of maize T25 and its conventional 
counterpart were carried out in 3 locations in France in 1999
22
 and in 12 European locations in 2000, 4 
                                                     
22 Technical dossier /Oberdoerfer (2002a). 
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each in Germany, France and Spain.
23
 A randomised complete block design with four replications in 
1999 and three replications in 2000 was used. The treatments included plots with T25 maize treated 
with a glufosinate-ammonium-containing herbicide, T25 maize treated with maintenance pesticides, 
and the conventional counterpart treated with the same maintenance pesticides. In the 1999 field trials, 
the T25 event was tested in two different maize genetic backgrounds, i.e. in Cecilia [LL (Liberty 
Link®) Moldova] and Torino (LL Kingston). The pedigree of the comparators indicated a genetic 
background very similar to those of the two maize T25 varieties. In the field trials in 2000, event T25 
was tested in Torino background (LL Kingston) in six locations and in Anjou 400 background (LL 
Anjou 400) in six locations.
24
 For additional analysis of the vitamin B6 content, the applicant 
performed an additional field trial in one location in the USA in 2006.
25
  
The four field trials performed in France in 2000 were used for studying the agronomic and 
phenotypic characteristics of maize T25 (treated and untreated with the target herbicide) and its 
conventional counterpart (Anjou 400 in two locations and Torino in two other locations) as well as for 
harvesting material for the compositional analysis.
26
 Additional agronomic information obtained from 
field trials performed in 1995 in Canada was also submitted by the applicant. 
An additional field trial for the agronomic and phenotypic characterisation was conducted in the 
2011/2012 growing season at two locations in São Desidério, Bahia, and Porto Nacional, Tocantins, in 
Brazil. Maize T25 and its conventional counterpart (the non-GM inbreed isoline B73) were used in a 
randomised complete block design with four replications. Maize T25 was used untreated (hand-
weeded) and treated with the intended herbicide (glufosinate-ammonium; 3.0 L/ha)
27
. 
In order to evaluate the levels of the various constituents analysed in maize T25 and its conventional 
counterpart, the applicant provided data from the literature on the ranges in the level of these 
constituents in maize kernels and derived products. 
4.1.2. Compositional analysis28 
Grain of field maize grown in Europe during the seasons of 1999 and 2000 was analysed for 
proximates and dietary fibre, as well as for free and total amino acids, free and total fatty acids, 
vitamins (B1, B2, B6
29
, niacin, pantothenic acid, folic acid, tocopherols), and for the anti-nutrient 
phytic acid. The selection of compounds concurred with the recommendations developed later by 
OECD (2002) except that various secondary analytes (raffinose, ferulic acid, p-coumaric acid, furfural, 
and trypsin inhibitor) have not been included. 
The outcome of the compositional analysis on field maize grain of T25 and its conventional 
counterparts grown in Europe in 1999 and 2000 indicated that the level of the majority of maize 
constituents were comparable, but that there were statistically significant differences across locations 
in copper, total palmitic acid and total linolenic acid. However, the differences were not observed at a 
majority of the locations when the data were analysed by location. The levels of these analytes fell 
within the background ranges obtained from the literature. 
The EFSA GMO Panel considered the observed compositional differences between grain produced 
from maize T25 and from its conventional counterpart in the light of the field trial design, measured 
biological variation and the level of the studied compounds in non-GM conventional varieties. The 
Panel concluded that no biologically relevant differences were identified in the compositional 
characteristics of grain produced from maize T25 compared with its conventional counterpart, and that 
                                                     
23 Technical dossier/Oberdoerfer (2002c, 2006b). 
24 Additional information September 2012. 
25 Technical dossier/Oberdoerfer (2007). 
26 Technical dossier/Oberdoerfer (2004b, 2006b). 
27 Additional information June 2013. 
28 Technical dossier/Section D7.1. 
29 Field trial performed in USA, 2006. 
Scientific opinion for the (continued) marketing of  
food and feed products derived from maize T25 
 
EFSA Journal 2013;11(10):3356 13 
its composition falls within the range of non-GM conventional varieties, except for the expression of 
the PAT protein. 
4.1.3. Agronomic traits and GM phenotype30 
The applicant presented agronomic and phenotypic data gathered from field trials with maize T25 
across two locations in Canada in 1995, four locations in France in 2000 and two locations in Brazil 
over the 2011–2012 growing season. The EFSA GMO Panel considered the field trials carried out in 
Canada in 1995 as not appropriate since neither a conventional counterpart nor the intended herbicide 
treatment of maize T25 were included. The GMO Panel considered that the French and Brazilian field 
trials were in accordance with the applicable guidance document (EFSA, 2006a). However, the Panel 
noted that only five endpoints (plant count, plant height, diameter ears/average diameter of the spikes, 




Of these five endpoints, only ‗time to anthesis‘ (across locations and in two locations) in France 
showed statistically significant differences in maize T25 compared with its conventional counterpart, 
while no statistically significant differences were observed in Brazil in 2011–2012.  
The EFSA GMO Panel examined other, publicly available agronomic and phenotypic data on maize 
T25 performance in variety trials which included a non-GM comparator. Maize variety Chardon LL 
containing the T25 event is reported to be similar to its conventional counterpart Orient (except for the 
glufosinate resistance trait). Maize variety Orient showed a field trial performance comparable to other 
non-GM maize varieties, as indicated in the national variety register of The Netherlands
32
. These 
reported summary data were insufficient for a full assessment by the EFSA GMO Panel owing to the 
limited availability of information on the study design and the statistical treatment of the data. 
Evaluating all the available data and evidence on agronomic and phenotypic characteristics of maize 
T25 and its comparators, the EFSA GMO Panel is of the opinion that no indication of unintended 
effects that might raise safety concerns was observed. 
4.2. Conclusion 
The EFSA GMO Panel concluded that the compositional, agronomic and phenotypic characteristics of 
maize T25 grain and its conventional counterpart showed no differences of relevance for food/feed 
safety.  
5. Food/feed safety assessment 
5.1. Evaluation of relevant scientific data  
5.1.1. Effect of processing33 
Maize T25 will be used for production and manufacturing of food and feed products in the same way 
as any other commercial maize variety.  
                                                     
30 Technical dossier/Section D7.4. 
31 Parameters measured: Canada 1995: plant count, moisture, yield, stalk and root lodging, plant disease; France 2000: time 
of anthesis, plant height, plant count, yield, length and diameter of ears; Brazil 2011–2012: shape of the first leaf tip, angle 
between leaf blade and stem, behaviour of the leaf blade above the upper spike, length of the main tassel stem, angle 
between the main tassel stem and the side branching, colour of the stigma by anthocyanin, male and female flowering, 
plant height, spike height, final stand, average length of the spike, average diameter of the spikes, number of kernels per 
row, spike stuffing degree, spike compaction, weight of 1 000 seeds, type of kernel. 
32 Dutch variety registration data on Chardon LL and its non-GM counterpart Orient: ―75e Rassenlijst voor 
Landbouwgewassen 2000‖ [75th List of Varieties of Field Crops 2000], Commissie voor de Samenstelling van de 
Rassenlijst voor Landbouwgewassen [Commission for the Compilation of the Variety List of Field Crops], p/a Centrum 
voor Plantenveredelings en Reproduktieonderzoek (CPRO) [c/o Center for Plant Breeding and Reproduction Research 
(CPRO)], Wageningen, the Netherlands, 2000, pp. 133–147. 
33 Technical dossier/Section D7.6. 
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The levels of the PAT protein in wet and dry milled field maize fractions as well as in processed sweet 
maize commodities were determined. For dry milling, the grains used for preparing the different 
matrices presented a PAT protein level of 130 ng/g. The PAT protein levels in the matrices were 
approximately 46 ng/g in hulls, 45 ng/g in grits, 17.2 ng/g in combined meal, 12.9 ng/g in flour and 
276 ng/g in germ. In crude and refined oil from maize T25 grains, the PAT protein was not detectable. 
For wet milling, the grains used for preparing the different matrices presented a PAT protein level of 
69.3 ng/g. The PAT protein levels in the matrices were approximately 7.7 ng/g in pressing cake from 
germs, 8.6 ng/g in meal after extraction of germs and 8.3 ng/g in meal after toasting germs. 
Taking into account the compositional analysis, providing no indication of biologically relevant 
compositional changes except for the PAT protein, the EFSA GMO Panel has no reason to assume 
that the characteristics of maize T25 and derived processed products would be different from those of 
the respective products derived from conventional maize varieties except for the presence of the newly 
expressed protein. 
5.1.2. Toxicology34 
5.1.2.1. Toxicological assessment of the newly expressed protein 
The EFSA GMO Panel has evaluated the safety of the PAT protein in the context of several previous 
applications and no concerns were identified (EFSA, 2005, 2006c, 2007a, b, c, 2008; EFSA GMO 
Panel, 2011c, 2012). 
In the current application (EFSA-GMO-RX-T25), an updated bioinformatic analysis of the amino acid 




5.1.2.2. Toxicological assessment of new constituents other than proteins 
No new constituents other than the PAT protein have been deliberately introduced into maize T25 and 
no biologically relevant changes in the composition of grain from maize T25 were detected (see 
Section 4.1.2). 
5.1.2.3. Animal studies with the food/feed derived from maize T25 
a) Sub-chronic toxicity study 
In a sub-chronic, 13-week rodent-feeding study, groups of 10 male and 10 female rats (strain Wistar 
Rj:WI (IOPS HAN)) received diets containing maize T25 milled maize at 33 % (w/w) and 11 % (w/w) 
inclusion levels (the former supplemented with 22 % B73 maize), the conventional counterpart B73 
(inclusion level 33 %) or the commercial reference Hybrid 8223 (inclusion level 33 %). 
Animals were housed in cages with five rats of the same sex per cage, but the data analysis considered 
the individual animal as the experimental unit, ignoring a possible bias due to cage interaction. Since 
the cage should be considered the experimental unit and because of the low number of experimental 
units per treatment (two per sex) a statistical analysis of the data is not possible. Therefore, the Panel 
did not consider this study in its evaluation. 
b) Chicken feeding study 
Reports of two 42-day feeding studies with broiler chickens were provided. In the first,
36
 a total of 280 
Ross  Ross male broiler chicks at hatch were subdivided into two groups, each group consisting of 
140 broilers housed in four pens. The two groups received diets containing grain from maize T25 (test 
group) or an unspecified non-GM commercial maize variety. Diets were formulated to meet the 
                                                     
34 Technical dossier/Section D7.8. 
35 Technical dossier/Section D7.8.1 and additional information September 2012. 
36 Technical dossier/Section D7.8.4/ Leeson (1996). 
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minimum nutrient requirements of a typical commercial broiler diet (NRC, 1994), and confirmed by 
the composition analysis of all diets. Each group of chickens was fed consecutively with starter, 
grower and finisher diets containing approximately 57 %, 61 % and 66 % of maize grain respectively.  
However, the EFSA GMO Panel was unable to consider the results from this study given the lack of a 
conventional counterpart as the control material for feed formulation, the low number of experimental 
units and the application of parametric statistical analysis.  
In the second 42-day feeding study,
37
 a total of 420 one-day-old chicken (Ross 708, half male and half 
female) were randomly assigned to one of the three treatments, each treatment consisting of 14 
replicate pens (seven pens per gender, 10 birds per pen). The diets, containing approximately 40 % 
maize grain, were formulated to meet poultry nutrient requirements and to be isocaloric and 
isonitrogenous, and balanced for limiting amino acids (analytically confirmed). Diets with the grains 
from the test diet (maize T25) contained the pat gene, but the control and the reference (non-GM 
commercial variety) diets did not. 
Effects on health, survival, live weight, total weight gain, feed consumption, feed to gain ratio, 
marketable carcass weight, muscle tissue weight and yield (breast, thigh, leg, wing), and abdominal fat 
pad weight were compared among groups. Body weight, weight gain, feed intake and feed to gain ratio 
was measured or calculated at weekly intervals until the end of the trial.  
Statistical evaluation was done by analysis of variance (ANOVA) using the replicates as experimental 
unit for survival, feed consumption and feed to gain ratio, and using the individual bird measurements 
for the other parameters. 
Overall mortality/culls was 6.4 % (27 birds). Post-mortem analysis showed inflammation of the 
kidney in seven birds, five of which also displayed splayed legs, myasthenia or lethargy. Deaths were 
not treatment related. 
Final body weight for females and males, respectively, were 2.51 and 2.78 kg in the T25 group, 2.44 
and 2.84 kg in the control group, and 2.43 and 2.76 kg in the reference group. The corresponding 
values for cumulative feed to gain ratio in females and males were 1.75 and 1.72 in the T25 group, 
1.79 and 1.69 in the control group, and 1.77 and 1.72 in the reference group. No significant differences 
were found for final body weight, weight gain, feed intake or feed to gain amongst males and females.  
However, as would be expected, females had a lower body weight than males. At study termination 
the subset of 42 randomly selected birds/treatment processed (three birds per cage) for carcass and 
tissue weights was examined for gross pathology. Three birds were found with enlarged spleens (two 
males in the T25 group, one male from the control group). Of the remaining 123 birds, carcass 
characteristics were not significantly different between groups. There was no significant treatment by 
gender interaction.  
Since all diets were designed to deliver the same nutrition, the expectation was that birds in the three 
groups would show essentially the same performance characteristics. The results confirmed the 
nutritional value of the maize T25 grain and the absence of unintended effects able to impact on 
growth at the level tested. 
5.1.3. Allergenicity38 
The strategies used when assessing the potential allergenic risk focus on the characterisation of the 
source of the recombinant protein, the potential of the newly expressed protein to induce sensitisation 
or to elicit allergic reactions in already sensitised persons and whether the transformation may have 
altered the allergenic properties of the modified plant. 
                                                     
37 Additional information September 2012/Stafford M-140202-02-1 (2010). 
38 Technical dossier/Section D7.9 and additional information received in September 2012. 
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5.1.3.1. Allergenicity assessment of the newly expressed protein 
A weight-of-evidence approach is followed, taking into account all of the information obtained with 
various test methods, since no single experimental method yields decisive evidence for allergenicity 
(Codex Alimentarius, 2009; EFSA, 2006a; EFSA GMO Panel, 2011a). 
The pat gene originates from Streptomyces viridochromogenes, a soil microorganism that is not 
known to be allergenic. 
In the current application (EFSA-GMO-RX-T25), an updated bioinformatic analysis
39
 of the amino 
acid sequence of the PAT protein using the criterion of 35 % identity in a window of 80 amino acids 
revealed no significant similarities to known allergens. In addition, the applicant performed an 
analysis
39
 searching for matches of eight contiguous identical amino acid sequences between the PAT 
protein and known allergens which confirmed the outcome of the previous bioinformatic analysis. 
The studies on resistance to degradation of the PAT protein by proteolytic enzymes presented in the 
current application have been previously assessed by the EFSA GMO Panel (2011c, 2012).  
The EFSA GMO Panel has evaluated the safety of the PAT protein in the context of several previous 
applications and no concerns in relation to allergenicity were identified (EFSA, 2005, 2006c, 2007a, b, 
c, 2008; EFSA GMO Panel, 2011c, 2012). 
Based on all the available information, the EFSA GMO Panel considered that there are no indications 
that the newly expressed PAT protein in maize T25 may be allergenic. 
5.1.3.2. Allergenicity assessment of the whole GM plant or crop 
According to the EFSA GMO Panel risk assessment guidelines (EFSA, 2006a; EFSA GMO Panel, 
2011a), the applicant should test any potential change in the allergenicity of the whole GM plant by 
comparing the allergen repertoire with that of its appropriate comparator(s), when the plant receiving 
the introduced gene is known to be allergenic. 
Maize has not been considered to be a common allergenic food
40
. The prevalence of food allergy to 
maize is low and appears to vary with the geographic location (Moneret-Vautrin et al., 1998; 
Pastorello et al., 2009; Fonseca et al., 2012). At least 23 IgE-binding proteins have been identified in 
maize, a number of which are recognised as allergens. Sixteen of these proteins have been reported to 
be stress related, with an LTP (lipid transfer protein) being the most important allergen (Pastorello et 
al., 2000, 2009; Pasini et al., 2002; Fonseca et al., 2012). In some studies, most individuals with a 
positive skin prick test or having IgE antibodies against maize were suffering from a respiratory 
allergy, and only a few displayed a true food allergy following oral challenge with maize products 
(Jones et al., 1995; Pasini et al., 2002). However, in another study of 27 patients with a claimed history 
of maize allergy, one-half were found to be challenge positive and thus had a food allergy to maize 
(Scibilia et al., 2008). 
Batista et al. (2005) carried out skin prick tests in 50 individuals (mean age 31 years) with asthma–
rhinitis, who were considered highly likely to have consumed products containing GM maize. Protein 
extracts from GM maize T25 and conventional maize were used, along with a number of other 
extracts.  Four individuals showed a positive skin prick reaction to conventional maize, with similar 
reactions to GM maize T25. No reactions to GM maize without an accompanying reaction of similar 
magnitude to conventional maize were observed. However, the study presents some limitations  
associated, for instance, with the low number of study subjects with a true food allergy to maize (in 
three of the four sensitive individuals the reactions to maize were likely to be due to cross-reactivity 
                                                     
39 Additional information received in September 2012. 
40
 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to 
Directive 2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ, L310, 11-14. 
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because of primary sensitisation to grass pollen). Despite the limitations, the study provides valuable 
supplementary information for the allergenicity assessment of the food/feed derived from maize T25.  
In the context of this application, and based on the available information, there is no evidence that the 
genetic modification might significantly change the overall allergenicity of maize T25. 
5.1.4. Nutritional assessment of GM food/feed 
The intended trait of maize T25 is herbicide tolerance, with no intention to alter the nutritional 
parameters. The outcome of the composition analysis (see Section 4.1.2) confirmed the nutritional 
equivalence of the food and feed products derived from maize T25. The introduction of these products 
into the food and feed chain is, therefore, expected to have no nutritional impact compared with its 
conventional counterpart and non-GM maize varieties.  
Phipps et al. (2005)
41
 divided 60 Holstein cows into four groups in a 12-week feeding study. Each 
group was fed silage from either maize T25, a near-isogenic non-GM maize or one of two commercial 
non-GM varieties. These four maize varieties were grown under similar general management 
conditions. Silage was then prepared from the four maize varieties. They were similar in the nutritive 
value, fermentation characteristics, mineral content and amino acid composition. The total mixed 
ration (TMR) contained 390 g silage dry matter per kg total dry matter (DM). 
DM intake of TMR was significantly lower for the near-isogenic diet than for the GM maize and the 
two commercial varieties. No significant differences between groups were observed in milk yield, 
milk composition, and yield of milk constituents. No tDNA of the event T25 or an endogenous 
Zea mays gene encoding the alcohol dehydrogenase was detected by PCR in 90 milk samples from the 
maize T25 group collected on weeks 1, 6, and 12 of the study. The PAT protein expressed by the T25 
maize was also not detected in milk by ELISA. 
Nutritional equivalence indicated by the compositional data was supported by the results of feeding 
studies with dairy cows (Phipps et al., 2005) and chickens (see Section 5.1.3.3b). The EFSA GMO 
Panel concluded that maize T25 is as nutritious as other maize varieties commercially available. 
5.1.5. Post-market monitoring of GM food/feed 
None of the available data indicates that maize T25 is any less safe or nutritious than its conventional 
counterpart. Therefore, in line with the guidance document (EFSA, 2006a; EFSA GMO Panel, 2011a), 
the EFSA GMO Panel concluded that post-market monitoring of the GM food/feed is not necessary. 
5.2. Conclusion 
The EFSA GMO Panel has evaluated the safety of the PAT protein in the context of the present 
application and several previous applications, and no safety concerns were identified (EFSA, 2005, 
2006c, 2007a, b, c, 2008; EFSA GMO Panel, 2011c, 2012).  
The compositional data indicating the nutritional equivalence of maize T25 were supported by the 
results of the feeding studies with dairy cow and chickens. In addition, there is no evidence that the 
genetic modification might significantly change the overall allergenicity of maize T25.  
6. Environmental risk assessment and monitoring plan 
6.1. Evaluation of relevant scientific data 
The scope of application EFSA-GMO-RX-T25 is for food and feed uses, import and processing of 
maize T25 and does not include cultivation. Considering the intended uses of maize T25, the 
environmental risk assessment is mainly concerned with ingestion by animals, and their manure and 
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faeces causing exposure of gastrointestinal tract and soil microorganisms, and with the accidental 
release into the environment of viable maize T25 grains during transport and/or processing. Maize T25 
was developed to express the enzyme phosphinothricin acetyl-transferase (PAT), encoded by the pat 
gene from Streptomyces viridochromogenes codon-optimised for expression in plants (see Section 
3.1.2). Expression of PAT confers tolerance to glufosinate-based herbicides. 
6.1.1. Environmental risk assessment 
6.1.1.1. Potential unintended effects on plant fitness due to the genetic modification 
Maize is highly domesticated and generally unable to survive in the environment without management 
intervention. Maize plants are not winter hardy in many regions of Europe; furthermore, they have lost 
their ability to release seeds from the cob and they do not occur outside cultivated land or disturbed 
habitats in agricultural landscapes of Europe, despite cultivation for many years. In cultivation, maize 
volunteers may arise under some environmental conditions (mild winters). Observations made on 
cobs, cob fragments or isolated grains shed in the field during harvesting indicate that grains may 
survive and overwinter in some regions, resulting in volunteers in subsequent crops. The occurrence of 
maize volunteers has been reported in Spain and other European regions (e.g. Gruber et al., 2008). 
However, maize volunteers have been shown to grow weakly and flower asynchronously with the 
maize crop (Palaudelmàs et al., 2009). 
In accordance with its guidance document on the environmental risk assessment of GM plants (EFSA 
GMO Panel, 2010), the EFSA GMO Panel follows a weight-of-evidence approach in collating and 
assessing appropriate information from various data sources (e.g. molecular and compositional data, 
available agronomic and phenotypic data from field trials performed by the applicant, literature) in 
order to assess the likelihood of unintended effects on the environment. The applicant provided 
molecular and compositional data that are assessed by the EFSA GMO Panel in Sections 3 and 4.1.2, 
respectively. In addition, the applicant presented agronomic and phenotypic data gathered from field 
trials with maize T25 across two locations in Canada in 1995, four locations in France in 2000 and two 
locations in Brazil over the 2011–2012 growing season (for further details, see Section 4.1.3).  





 variety trials in the UK, which assessed the variety‘s agronomic and phenotypic 
characteristics in comparison with commercial varieties. In addition, some agronomic parameters, 
such as crop height and plant density, were studied in the UK‘s Farm-Scale Evaluations (Champion et 
al., 2003; Hawes et al., 2003; Heard et al., 2003a, b; Firbank et al., 2006). Data from variety trials in 
the UK and by Hawes et al. (2003) showed that early in the season Chardon LL was slightly taller than 
comparator varieties, and data from variety trials in the UK show slightly later maturity characteristics. 
However, these differences in height were transient, and Chardon LL was similar in most other 
characteristics, including biomass yield, to the comparator varieties. Thus, Chardon LL has 
characteristics typical of other forage maize varieties and there are no indications of any significant 
changes to its agronomic characteristics. In addition, Crawley et al. (2001) studied the fate of sown 
individuals, to measure recruitment over multiple seasons in various locations, in order to determine 
whether the GM maize would be more invasive or more persistent in natural habitats than a non-GM 
comparator. The authors assessed the GM maize, recording its growth, mortality, flowering and seed 
set over time, and concluded that there were no indications of changes in the establishment, 
persistence and invasiveness of the GM maize that would indicate a change in its ferality.  
Moreover, the EFSA GMO Panel is not aware of any further scientific report of increased spread and 
establishment of maize T25 or maize with comparable properties or of any change in survival 
capacity, including overwintering.  
                                                     
42 DUS tests = tests to establish if the new variety is clearly distinguishable from all other existing varieties within the crop 
concerned (Distinct), whether the variety remains uniform during propagation (Uniform) and whether the characteristics of 
the variety remain stable during repeated propagation (Stable).  
43 VCU tests = tests to check the Value for Cultivation and Use of the new variety. 
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Considering all available information related to the agronomic and phenotypic characterisation of 
maize T25, the EFSA GMO Panel did not observe any enhanced fitness characteristics of maize T25 
that would change its capacity to spread, establish or persist compared with non-GM maize, except in 
the presence of glufosinate-based herbicides. Therefore, the EFSA GMO Panel concludes that, 
considering the scope of this application, the weight of available evidence and the poor ability of 
maize to survive outside cultivated land, there were no indications that maize T25 would differ in 
environmental impacts if there was accidental release into the environment of viable grains. 
6.1.1.2. Potential for gene transfer 
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic material, 
either horizontal gene transfer of DNA or vertical gene transfer via seed spillage followed by cross-
pollination. 
a) Plant-to-bacteria gene transfer  
Genomic plant DNA is a component of several food and feed products derived from maize. It is well 
documented that DNA present in food and feed becomes substantially degraded during processing and 
digestion in the human or animal gastrointestinal tract. However, a low level of exposure of fragments 
of ingested DNA, including the recombinant fraction of such DNA, to bacteria in the digestive tract of 
humans, domesticated animals and other environments exposed to the GM plant or plant material is 
expected. 
Current scientific knowledge of recombination processes in bacteria suggests that horizontal transfer 
of non-mobile, chromosomally located DNA fragments between unrelated organisms (such as plants 
to bacteria) is not likely to occur at detectable frequencies under natural conditions (for further details, 
see EFSA, 2009). 
A successful horizontal gene transfer would require stable insertion of the transgene sequences into a 
bacterial genome and a selective advantage to be conferred on the transformed host. The only 
mechanism known to facilitate horizontal transfer of non-mobile, chromosomal DNA fragments to 
bacterial genomes is homologous recombination (HR). The similarity between the plant and bacterial 
sequences can be situated in the transgene itself or in the flanking regions. In the case of sequence 
similarity between the transgenic DNA and the natural variants of the gene in bacteria, recombination 
could result in a gene replacement in bacteria. 
Maize T25 contains the following recombinant DNA sequences: the 35S promoter from Cauliflower 
mosaic virus (CaMV), a pat gene from Streptomyces viridochromogenes codon-optimised for 
expression in plants, and the 35S transcription terminator from CaMV (for further details, see Section 
3). The modified pat gene shows high similarity to a bacterial gene which could theoretically provide 
sites for homologous recombination and thus promote horizontal gene transfer. Furthermore, the plant 
DNA contains at the 5  end of the integrated T25 expression cassette 604 bp of DNA derived from the 
Escherichia coli cloning vector pUC18), which consists of a fragment of the lacZ gene. In addition, at 
the 3  end of the integrated T25 expression cassette, the plant DNA contains 1 840 bp of the plasmid 
including a 665-bp fragment of a -lactam antibiotic resistance gene (bla gene) and the origin of 
replication (ori) of the pUC18 (which originates from plasmid pMB1 of an E. coli strain used to 
construct plasmid pBR322).  
The modified pat gene, optimised for expression in plants, originates from S. viridochromogenes, 
which is a member of the phylum Actinobacteria. Natural variants of the pat gene (i.e. bar, hpat, mat) 
have been found in other bacteria with the capacity to produce the amino acid phosphinothricin 
(glufosinate), among them the Actinobacteria Streptomyces hygroscopicus and Kitasatospora 
phosalacinea. All of these bacteria are considered to be spore-forming soil bacteria and not to be 
regular inhabitants of the gastrointestinal tract of humans or animals. Owing to the potential for wide 
environmental distribution of bacterial spores, however, it cannot be excluded that spores of S. 
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viridochromogenes or other Actinobacteria may also occasionally occur in these main receiving 
environments. Furthermore, outside this main route of exposure through food and feed uses, 
recombinant DNA of maize T25 may also accidentally come in contact with such Actinobacteria in 
soil. Therefore, various routes of exposure were considered here. 
On a theoretical basis (i.e. in the absence of experimental evidence of horizontal gene transfer in GM 
food and feed derived from maize T25 or any other GM plant), it can be assumed that, as an extremely 
rare event, HR may occur between the recombinant pat gene and their natural variants (i.e. pat, bar, 
hpat, mat) in the environments described above.  
The DNA sequence similarity between the plasmid region including the origin of replication (length 
1 177 bp) and the -lactam antibiotic resistance gene fragment (length 665 bp) and the corresponding 
genes in natural plasmids of E. coli, and possibly other Enterobacteriaceae, potentially facilitates HR 
between the transgenic DNA sequences and those plasmids as they may occur in E. coli and other 
Enterobacteriaceae. In fact, E. coli and other Enterobacteriaceae are present in the main receiving 
environment, i.e. the gastrointestinal tract. However, because of the molecular structure (direct vicinity 
of both sequences), such a recombination process would not result in the acquisition of an additional 
gene and therefore no novel selective advantage would be provided. 
Theoretically, double homologous recombination between the oriV and/or bla sequences and the lacZ 
sequences could result in the insertion of the pat gene onto pUC/pBR322-like plasmids of E. coli 
(cloning vectors) or into the chromosome. The chromosomal recombination is unlikely to result in 
viable bacteria with a pat gene since the double homologous recombination would cause a deletion of 
other chromosomal genes located between the two genetic elements (bla and lacZ sequences). Only 
cloning vectors, i.e. pUC or pBR322 with a bla gene, could function as recipient molecules, if they 
occurred as contaminants in the environment. Therefore, scenarios in which the pat gene would be 
transferred from DNA of maize T25 to synthetic resistance plasmids were also considered here in 
assessing the risk for horizontal gene transfer (see below). 
In addition to homology-based recombination processes, illegitimate recombination that does not 
require similarity between the recombining DNA molecules is theoretically possible. However, 
transformation rates for illegitimate recombination are considered to be 10
10
-fold lower than for 
homologous recombination (Hülter and Wackernagel, 2008; EFSA, 2009). Illegitimate recombination 
events have not been detected in studies that have exposed bacteria to high concentrations of GM plant 
DNA (EFSA, 2009). Thus, this process, compared with homologous recombination, is considered not 
to contribute significantly to horizontal gene transfer events. In comparison with the above-described 
homology-facilitated recombination processes, the contribution of illegitimate recombination is 
extremely low. 
Owing to the bacterial origin of the pat gene and the prevalence of bacterial genes encoding for the 
enzyme phosphinothricin acetyl-transferase in the environment, a low-level gene transfer to 
S. viridochromogenes or other bacterial species, including a transfer onto plasmids, is thought not to 
confer a new trait and selective advantage. Considering its intended uses as food and feed and the 
above assessment, the EFSA GMO Panel has therefore not identified a concern associated with a 
potential horizontal gene transfer from maize T25 to bacteria. 
b) Plant-to-plant gene transfer 
Considering the intended uses of maize T25 and the physical characteristics of maize seeds, possible 
pathways of gene dispersal are grain spillage and the dispersal of pollen from occasional feral GM 
maize plants originating from accidental grain spillage during transport and/or processing. 
The extent of cross-pollination to other maize varieties will mainly depend on the scale of accidental 
release during transport and/or processing and on successful establishment and subsequent flowering 
of this GM maize plant. For maize, any vertical gene transfer is limited to other Zea mays plants as 
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populations of sexually compatible wild relatives of maize are not known in Europe (Eastham and 
Sweet, 2002; OECD, 2003). 
The flowering of occasional feral GM maize plants originating from accidental release during 
transport and/or processing is unlikely to disperse significant amounts of GM maize pollen to other 
maize plants. Field observations performed on maize volunteers after GM maize cultivation in Spain 
revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that cross-
pollinated neighbour plants only at low levels (Palaudelmàs et al., 2009). 
Although GM maize plants outside cropped areas have been reported in Korea, as a result of grain 
spillage during import, transport, storage, handling and processing (Kim et al., 2006; Lee et al., 2009; 
Park et al., 2010), survival of maize plants outside cultivation in Europe is mainly limited by a 
combination of low competitiveness, absence of a dormancy phase and susceptibility to plant 
pathogens, herbivores and frost. As for any other maize varieties, GM maize plants would only survive 
in subsequent seasons in warmer regions of Europe and are not likely to establish feral populations 
under European environmental conditions. 
The EFSA GMO Panel takes into account the fact that this application does not include cultivation of 
maize T25 within the EU so that the likelihood of cross-pollination between cultivated maize and the 
occasional feral maize plants resulting from grain spillage is considered extremely low. In conclusion, 
considering the scope of this application, a weight-of-evidence approach and the poor ability of maize 
to survive outside cultivated land, the EFSA GMO Panel is of the opinion that there is very little 
likelihood of adverse environmental effects as a consequence of spread of genes from this GM maize 
in Europe. 
6.1.1.3. Potential interactions of the GM plant with target organisms  
Considering the intended uses of maize T25, excluding cultivation, and the absence of target 
organisms, potential interactions of the GM plant with target organisms were not considered an issue 
by the EFSA GMO Panel. 
6.1.1.4. Potential interactions of the GM plant with non-target organisms 
Owing to the intended uses of maize T25, which exclude cultivation, and the low level of exposure to 
the environment, potential interactions of the GM plant with non-target organisms were not considered 
an issue by the EFSA GMO Panel. 
6.1.1.5. Potential interaction with the abiotic environment and biogeochemical cycles 
Owing to the intended uses of maize T25, which exclude cultivation, and the low level of exposure to 
the environment, potential interactions with the abiotic environment and biogeochemical cycles were 
not considered an issue by the EFSA GMO Panel 
6.2. Post-market environmental monitoring 
The objectives of a post-market environmental monitoring (PMEM) plan according to Annex VII of 
Directive 2001/18/EC are (1) to confirm that any assumption regarding the occurrence and impact of 
potential adverse effects of the GMO, or its use, in the environmental risk assessment are correct; and 
(2) to identify the occurrence of adverse effects of the GMO, or its use, on human health or the 
environment that were not anticipated in the environmental risk assessment. 
Monitoring is related to risk management, and thus a final adoption of the PMEM plan falls outside 
the mandate of EFSA. However, the EFSA GMO Panel gives its opinion on the scientific content of 
the PMEM plan provided by the applicant (EFSA GMO Panel, 2011b). The potential exposure to the 
environment of maize T25 would be mainly through ingestion by animals, and their manure and faeces 
leading to exposure of gastrointestinal tract and soil microorganisms, and with the accidental release 
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into the environment of viable maize T25 grains during transport and/or processing. The scope of the 
PMEM plan provided by the applicant is in line with the intended uses. As the environmental risk 
assessment did not identify potential adverse environmental effects due to maize T25, no case-specific 
monitoring is required. 
The PMEM plan proposed by the applicant includes (1) the description of an approach involving 
operators (federations involved in maize import and processing) reporting to the applicant, via a 
centralised system, any observed adverse effect(s) of GMOs on human health and the environment; (2) 
a coordinating system established by EuropaBio for the collection of the information recorded by the 
various operators; and (3) the use of networks of existing surveillance systems (Lecoq et al., 2007; 
Windels et al., 2008). The applicant proposes to submit a PMEM report on an annual basis. 
The EFSA GMO Panel is of the opinion that the scope of the PMEM plan proposed by the applicant is 
in line with the intended uses of maize T25 as the environmental risk assessment did not cover 
cultivation and identified no potential adverse environmental effects. The EFSA GMO Panel agrees 
with the reporting intervals proposed by the applicant in the PMEM plan. 
6.3. Conclusion 
Considering the intended uses of maize T25, the environmental risk assessment is concerned with 
indirect exposure, mainly through ingestion by animals, and their manure and faeces resulting in 
exposure of gastrointestinal tract and soil microorganisms, and with the accidental release into the 
environment of viable maize T25 grains during transport and/or processing.  
Considering all available information related to the agronomic and phenotypic characterisation of 
maize T25, the EFSA GMO Panel did not observe any enhanced fitness characteristics of maize T25 
that will change its capacity to spread, establish or persist compared with non-GM maize, except in the 
presence of glufosinate-based herbicides. Considering its intended uses as food and feed, interactions 
with the biotic and abiotic environment were not considered to be an issue. Risks associated with an 
unlikely but theoretically possible horizontal gene transfer from maize T25 to bacteria have not been 
identified. The scope of the PMEM plan provided by the applicant and the reporting intervals are in 
line with the intended uses of maize T25 and the guidance document of the EFSA GMO Panel on 
PMEM of GM plants (EFSA GMO Panel, 2011b). The EFSA GMO Panel agreed with the reporting 
intervals proposed by the applicant in the PMEM plan. 
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7. Overall conclusion for application EFSA-GMO-RX-T25 
The molecular characterisation data established that the genetically modified maize T25 contains a 
single insertion locus containing a pat cassette. Bioinformatic analyses, protein expression data and 
genetic stability studies did not raise safety issues.  
The compositional, agronomic and phenotypic characteristics of grain maize T25 and its conventional 
counterpart showed no differences of relevance for food/feed safety. The EFSA GMO Panel has 
evaluated the safety of the PAT protein in the context of the present application and several previous 
applications, and no safety concerns were identified. Data from nutritional studies with whole 
food/feed did not raise any safety concern. There was no evidence that the genetic modification might 
significantly change the overall allergenicity of maize T25.  
The environmental risk assessment did not identify evidence of any adverse environmental impacts 
due to the accidental release into the environment of viable grains from maize T25. No data indicating 
adverse impacts to human/animal health and the environment have emerged since the authorisation of 
maize T25. 
The scope of the PMEM plan provided by the applicant and the reporting intervals are in line with the 
intended uses of maize T25 and the guidance document of the EFSA GMO Panel on PMEM of GM 
plants (EFSA GMO Panel, 2011b). In addition, the EFSA GMO Panel acknowledged the approach 
proposed by the applicant to put in place appropriate management systems to restrict environmental 
exposure in cases of accidental release of viable seeds of maize T25. The EFSA GMO Panel agreed 
with the reporting intervals proposed by the applicant in the PMEM plan. 
In conclusion, the EFSA GMO Panel considered that the information available for maize T25 
confirms the previous opinions on its safety (SCP, 1998; ACNFP, 2003) and allows the Panel to 
conclude that maize T25 is as safe as its conventional counterpart with respect to potential effects on 
human and animal health or the environment in the context of its intended uses. 
8. Risk assessment and overall conclusion for application EFSA-GMO-NL-2007-46 
The scope of application EFSA-GMO-NL-2007-46 includes food containing or consisting of maize 
T25 in addition to the scope of EFSA-GMO-RX-T25 (food and food ingredients produced from maize 
T25 and feed containing, consisting of or produced from maize T25). Considering the scope of the two 
applications, the risk assessment and conclusions drawn for maize T25 in EFSA-GMO-RX-T25 are 
valid for maize T25 in the context of application EFSA-GMO-NL-2007-46. Therefore, the EFSA 
GMO Panel considered that maize T25, as described in application EFSA-GMO-NL-2007-46, is as 
safe as its conventional counterpart with respect to potential effects on human and animal health or the 
environment in the context of its intended uses. 
OVERALL CONCLUSIONS 
In conclusion, the EFSA GMO Panel considered that maize T25, as described in applications EFSA-
GMO-RX-T25 and EFSA-GMO-NL-2007-46, is as safe as its conventional counterpart with respect to 
potential effects on human and animal health or the environment in the context of its intended uses for 
food and feed, import and processing. 
DOCUMENTATION PROVIDED TO EFSA IN RELATION TO EFSA-GMO-RX-T25 
1. Letter from the European Commission, received on 29 June 2007, concerning a request for 
renewal of authorisation for the placing on the market of genetically modified maize T25 
submitted in accordance with articles 8(1)(a) and 20(1)(a),(b) of Regulation (EC) No 
1829/2003. 
2. Acknowledgement letter, dated 20 July 2007, from EFSA to the European Commission. 
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3. Letter from EFSA to applicant, dated 7 March 2008, requesting additional information under 
completeness check. 
4. Letter from applicant to EFSA, received on 3 October 2008, providing additional information 
under completeness check. 
5. Letter from EFSA to applicant, dated 9 October 2008, delivering the ―Statement of Validity‖ for 
application EFSA-GMO-RX-T25, regarding genetically modified maize T25 submitted under 
Regulation (EC) No 1829/2003 by Bayer. 
6. Letter from EFSA to applicant, dated 9 October 2008, concerning EFSA-GMO-NL-2007-46 
and EFSA-GMO-RX-T25 and stopping the clock. 
7. Letter from applicant to EFSA, received on 1 September 2010, providing additional information 
concerning T25. 
8. Letter from EFSA (UK CA) to applicant, dated 8 September 2010, restarting the clock. 
9. Letter from EFSA to applicant, dated 29 March 2012, requesting additional information and 
stopping the clock. 
10. Letter from EFSA to applicant, dated 24 May 2012, requesting additional information and 
maintaining the clock stopped. 
11. Letter from EFSA to applicant, dated 11 July 2012, concerning finalisation of the EFSA 
assessment. 
12. Letter from applicant to EFSA, dated 20 August 2012, concerning finalisation of the EFSA 
assessment. 
13. Letters from applicant to EFSA, received on 3 September 2012, providing additional 
information. 
14. Letter from EFSA to applicant, dated 15 October 2012, concerning finalisation of the EFSA 
assessment. 
15. Letter from EFSA to applicant, dated 18 October 2012, restarting the clock. 
16. Letter from applicant to EFSA, received on 18 December 2012, providing additional 
information. 
17. Letter from applicant to EFSA, received on 14 January 2013, concerning change of scope. 
18. Letter from EFSA to applicant, dated 4 February 2013, requesting additional information and 
stopping the clock. 
19. Letter from applicant to EFSA, received on 19 February 2013, providing additional information. 
20. Letter from EFSA to applicant, dated 27 May 2013, restarting the clock. 
21. Letter from applicant to EFSA, received on 29 May 2013, indicating availability to provide 
additional information. 
22. Letter from EFSA to applicant, dated 30 May 2013, referring to letter sent on 11 July 2012. 
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23. Letter from applicant to EFSA, received on 26 June 2013, providing spontaneous additional 
information. 
DOCUMENTATION PROVIDED TO EFSA IN RELATION TO EFSA-GMO-NL-2007-46 
1. Letter from the Competent Authority of the Netherlands, received on 24 April 2007, concerning 
a request for the placing on the market of genetically modified maize T25 submitted under 
Regulation (EC) No 1829/2003 by Bayer. 
2. Acknowledgement letter, dated 12 July 2007, from EFSA to the Competent Authority of the 
Netherlands. 
3. Letter from EFSA to applicant, dated 4 October 2007, requesting additional information under 
completeness check. 
4. Letter from applicant to EFSA, received on 23 May 2008, providing additional information 
under completeness check. 
5. Letter from EFSA to applicant, dated 10 June 2008, delivering the ―Statement of Validity‖ for 
application EFSA-GMO-NL-2007-46, regarding genetically modified maize T25 submitted 
under Regulation (EC) No 1829/2003 by Bayer. 
6. Letter from EFSA (UK CA) to applicant, dated 1 October 2008, requesting additional 
information and stopping the clock. 
7. Letter from EFSA to applicant, dated 9 October 2008, concerning EFSA-GMO-NL-2007-46 
and EFSA-GMO-RX-T25. 
8. Letter from applicant to EFSA (UK CA), received on 1 July 2009, providing additional 
information. 
9. Letter from EFSA (UK CA) to applicant, dated 24 June 2010, restarting the clock. 
10. Letter from applicant to EFSA, received on 1 September 2010, providing additional information 
concerning T25. 
11. Letter from applicant to EFSA, received on 7 October 2010, providing additional information 
concerning T25. 
12. Letter from EFSA to applicant, dated 29 March 2012, requesting additional information and 
stopping the clock. 
13. Letter from EFSA to applicant, dated 24 May 2012, requesting additional information and 
maintaining the clock stopped. 
14. Letter from EFSA to applicant, dated 11 July 2012, concerning finalisation of the EFSA 
assessment. 
15. Letter from applicant to EFSA, dated 20 August 2012, concerning finalisation of the EFSA 
assessment. 
16. Letters from applicant to EFSA, received on 3 September 2012, providing additional 
information. 
17. Letter from EFSA to applicant, dated 15 October 2012, concerning finalisation of the EFSA 
assessment. 
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18. Letter from EFSA to applicant, dated 18 October 2012, restarting the clock. 
19. Letter from applicant to EFSA, received on 18 December 2012, providing additional 
information. 
20. Letter from applicant to EFSA, received on 14 January 2013, concerning change of scope. 
21. Letter from EFSA to applicant, dated 4 February 2013, requesting additional information and 
stopping the clock. 
22. Letter from applicant to EFSA, received on 19 February 2013, providing additional information. 
24. Letter from EFSA to applicant, dated 27 May 2013, restarting the clock. 
25. Letter from applicant to EFSA, received on 29 May 2013, indicating availability to provide 
additional information. 
26. Letter from EFSA to applicant, dated 30 May 2013, referring to letter sent on 11 July 2012. 
23. Letter from applicant to EFSA, received on 26 June 2013, providing spontaneous additional 
information. 
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